It analyzes pathway-level variants (GLP1R (rs6923761), and GIPR (rs1800437)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction
Research Dosages and Protocols * Note: The listed dosages are based on reference research models and should be adapted to the specific requirements of your laboratory protocol
TB-500 represents an intriguing area of emerging clinical application for long COVID patients dealing with any of the following concerns: Neurological symptoms Cognitive impairment Tissue damage associated with prolonged inflammation KPV and Immune-Gut Axis Modulation KPV is a tripeptide derived from alpha-melanocyte-stimulating hormone (alpha-MSH) with potent anti-inflammatory effects, particularly in the gut
Lifford KL and Curhan GC: Prevalence of painful bladder syndrome in older women
This does not mean compounded products are unsafe
They target the same outcome (tissue repair) through different mechanisms : BPC-157: local growth factor expression, fibroblast stimulation, angiogenesis at the injury site TB-500: systemic cell migration, actin regulation, reduction of chronic inflammation throughout the body Standard Wolverine stack: BPC-157: 250500 mcg SC twice daily , injected near the injury site where possible TB-500: 22.5 mg SC twice weekly loading (weeks 14), then 2 mg weekly maintenance (weeks 512) CRITICAL: do not mix in the same vial - they can be injected in the same session but must remain in separate solutions
